Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensedPOCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.
Company profile
Ticker
ORGS
Exchange
Website
CEO
Vered Caplan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Business Outsourcing Service, Inc.
SEC CIK
Corporate docs
Subsidiaries
Orgenesis Korea Co. Ltd. • Orgenesis Belgium SRL • Orgenesis Ltd. • Orgenesis Maryland Inc. • Orgenesis Switzerland Sarl • Orgenesis Biotech Israel Ltd. • Koligo Therapeutics Inc. • Orgenesis Germany GmbH • Orgenesis CA, Inc. ...
IRS number
980583166
ORGS stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
18 Jan 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 22
8-K
Amendments to Articles of Incorporation or Bylaws
19 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Entry into a Material Definitive Agreement
7 Nov 22
DEF 14A
Definitive proxy
1 Nov 22
8-K
Entry into a Material Definitive Agreement
27 Oct 22
8-K
Entry into a Material Definitive Agreement
17 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Nov 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.47 mm | 4.47 mm | 4.47 mm | 4.47 mm | 4.47 mm | 4.47 mm |
| Cash burn (monthly) | (no burn) | 911.42 k | 461.00 k | 1.48 mm | 1.65 mm | 1.39 mm |
| Cash used (since last report) | n/a | 3.96 mm | 2.00 mm | 6.41 mm | 7.17 mm | 6.01 mm |
| Cash remaining | n/a | 510.96 k | 2.47 mm | -1.95 mm | -2.71 mm | -1.55 mm |
| Runway (months of cash) | n/a | 0.6 | 5.3 | -1.3 | -1.6 | -1.1 |
Institutional ownership, Q3 2022
13.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 22 |
| Opened positions | 4 |
| Closed positions | 4 |
| Increased positions | 4 |
| Reduced positions | 7 |
| 13F shares | Current |
|---|---|
| Total value | 6.07 mm |
| Total shares | 3.55 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Knoll Capital Management | 1.32 mm | $1.87 mm |
| Vanguard | 924.35 k | $1.31 mm |
| Bergen Asset Management | 710.12 k | $2.05 mm |
| Geode Capital Management | 199.56 k | $283.00 k |
| BLK Blackrock | 120.45 k | $171.00 k |
| Ronit Capital | 54.17 k | $77.00 k |
| Renaissance Technologies | 51.00 k | $72.00 k |
| NTRS Northern Trust | 36.23 k | $51.00 k |
| BKHPF Bank Hapoalim BM | 32.05 k | $46.00 k |
| Susquehanna International | 29.27 k | $42.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Dec 22 | Adler Yaron | Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 15,000 | 27.90 k | 15,000 |
| 23 Dec 22 | Nanda Ashish | Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 15,850 | 29.48 k | 15,850 |
| 23 Dec 22 | Philips Mario | Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 13,750 | 25.58 k | 13,750 |
| 23 Dec 22 | Sidransky David | Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 20,450 | 38.04 k | 20,450 |
| 23 Dec 22 | Yachin Guy | Stock Option Common Stock | Grant | Acquire A | No | No | 1.86 | 19,600 | 36.46 k | 19,600 |
News
Orgenesis's Return On Capital Employed Insights
22 Dec 22
Orgenesis And Kurve Therapeutics Announce Pre-Clinical Study Results For A Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction In A Murine Glioblastoma Model
20 Dec 22
12 Health Care Stocks Moving In Thursday's After-Market Session
24 Nov 22
12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Nov 22
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
14 Nov 22